FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
COLPAL Consensus Forecast
No. of reports in last year
13
No. of analysts
6
Average Consensus Forecast
1718.62
Consensus Potential
-0.99%
COLPAL Price Target Potential
| Brokerage | Target | Potential |
|---|---|---|
| Sharekhan | 1950 | 11.77% |
| ICICIdirect.com | 2000 | 13.98% |
| Nirmal Bang | 1755 | 1.97% |
| Prabhudas Lilladher | 1846 | 6.80% |
| Motilal Oswal | 1700 | -1.20% |
COLPAL Ratings
Long term COLPAL rating by FrontPage users
- ★★
- ★★
- ★★
- ★★
- ★★
3.5/5 (8 Ratings)
13 COLPAL share price target reports by brokerages below. See what is analyst's view on COLPAL share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
- Home
- COLPAL Forum
- COLPAL Price Target
COLPAL Share Price Target
COLPAL Share Price Target - Broker Reports - 2021
Sharekhan
29-Jul-21
Price @ Call: 1709
Target: 1950
BUY
ICICIdirect.com
30-Jul-21
Price @ Call: 1704.25
Target: 2000
BUY
Nirmal Bang
29-Jul-21
Price @ Call: 1709.1
Target: 1755
ACCUMULATE
Prabhudas Lilladher
29-Jul-21
Price @ Call: 1709.1
Target: 1846
ACCUMULATE
Motilal Oswal
17-May-21
Price @ Call: 1596
Target: 1700
NEUTRAL
ICICIdirect.com
18-May-21
Price @ Call: 1580.5
Target: 1900
BUY
Nirmal Bang
18-May-21
Price @ Call: 1580.5
Target: 1700
ACCUMULATE
Prabhudas Lilladher
28-Jan-21
Price @ Call: 1563.06
Target: 1651
HOLD
COLPAL Share Price Target - Broker Reports - 2020
Nirmal Bang
21-Dec-20
Price @ Call: 1563.84
Target: 1610
ACCUMULATE
Axis Direct
21-Oct-20
Price @ Call: 1442.34
Target: 1565
BUY
ICICIdirect.com
22-Oct-20
Price @ Call: 1425.35
Target: 1700
BUY
Nirmal Bang
22-Oct-20
Price @ Call: 1425.35
Target: 1520
ACCUMULATE
Prabhudas Lilladher
22-Oct-20
Price @ Call: 1425.35
Target: 1445
HOLD
Axis Direct
9-Sep-20
Price @ Call: 1363.55
Target: 1565
BUY
Prabhudas Lilladher
29-Jul-20
Price @ Call: 1428.32
Target: 1344
REDUCE
We are increasing FY21,22,23 EPS estimates of CLGT by 8.2%, 5.7% and 4.8% led by 1) lower volume decline of 6% in toothpaste, and largely normal production now 2) Trade inventory buildup in June which continues in 2Q as well 3) superior on shelf availability relative to Patanjali, Vicco and other herbal brands 4) 300bps cut in 1Q adspends, only gradual restoration in 2Q and 5) improved realizations on lower discounts. CLGT is upping the ante to regain lost share by 1) increasing adspends 2) sustained innovations (Bamboo Toothbrush, Charcoal Toothpaste etc.) and 3) distribution clout. We believe retaining new customers would be a challenge given new launches by Dabur (Ayurvedic Paste) and Vicco (Saunf) in fast growing herbal segment. We remain highly skeptical of sustained growth in non- oral care portfolio (despite 60% growth in hand wash in 1Q21) like Handwash, Sanitizers, Body wash, Bath Soaps and Shampoos given lack of in-house manufacturing, limited media push and visibility. We estimate 7.7% PAT CAGR over FY20-23 and value the stock at 37xSept22EPS ( 20% discount to HUVR target PE) and arrive at a target price of Rs 1344 (Rs1277@37xSept22EPS) Retain Reduce.
Sushil Finance
26-May-20
Price @ Call: 1286.26
Target: 1640
BUY
Colgate Palmolive (India) Ltd results were slightly below expectations in terms of revenue numbers. However, we have taken the impact of COVID19 under consideration and arrived at a FY22E PAT and EPS of Rs. 989.9 Cr and Rs.36.40 respectively. We maintain our revenue growth forecast of ~3% CAGR over FY19-22E and assign a price multiple of ~45 maintaining our target price of Rs.1,640 over a period of 18-24 month investment horizon which gives an upside of ~24% from today’s opening price.
Angel Broking
23-May-20
Price @ Call: 1326.9
Target: 1588
BUY
We believe that the CPIL will ultimately be able to see sharper market share gains in toothpastes segment on the back of higher ad-spends, new product launches, strong brand and wide distribution network. Thus, we maintain BUY on the stock with Target Price of Rs1,588.
Nirmal Bang
22-May-20
Price @ Call: 1326.9
Target: 1375
ACCUMULATE
Due to pain in the near term, we have cut our earnings estimates by 12.6%/10.2% for FY21E/FY22E. While we appreciate the management’s decision to invest heavily in advertisement & promotions to drive volume-led sales growth we still await any signs of improvement in market share on a full year basis. Per capita consumption remains a big opportunity in the toothpaste category and the company’s strategy now to take its Bright Smiles Bright Future (BSBF) campaign to urban areas as well, can increase urban consumption in future. Higher rural salience compared to other peers also remains an important driver as and when the hinterlands recover. The stock is up ~12% from our recent upgrade note and now trades at 44x/38x FY21/FY22 EPS. We value the company at 40x FY22E EPS, giving us a target price (TP) of Rs1,375, implying a limited upside of 5% from CMP. We thus downgrade the stock to Accumulate from Buy earlier.
Prabhudas Lilladher
22-May-20
Price @ Call: 1326.9
Target: 1224
REDUCE
We are cutting FY21 and 22 EPS estimates of CLGT by 7.1% and 3.9% respectively based on 1) Covid impact on production and sales in 1Q 2) delayed recovery post Covid in higher dependence on wholesale channel and 3) delay in opening of high focus modern trade in top cities. Mgt strategy is now centered on 1) gaining share in urban India with value added premium products (Bamboo Toothbrush, Charcoal Toothpaste and naturals segment 2) calibetated approach to grow Palmolive business with launch of premium body wash, hand wash and entry in Shampoo and Sanitizers and 3) sustained investment (advertising) even during lockdown period. We believe, gaining market share remains key for CLGT given high category penetration. We note that CLGT grew sales by 15.2% and EBIDTA by 18.4% CAGR over FY05-15 as it gained 11.6% toothpaste market share (46.2% to 57.9%) at the expense of HUL, however loss of ~750bps share since FY15 resulted in just 2.6% sales and 8.2% EBIDTA CAGR. Gaining market share looks a challenge given strong presence of Dabur, Patanjali and Vicco in fast growing herbal segment. We estimate 5.2% PAT CAGR over FY20-22 and value the stock at 37xFY22EPS (earlier 35x, 20% discount to HUVR target PE) and arrive at a target price of Rs 1224. We recommend switch from Colgate to HUVR. Retain Reduce.
Sushil Finance
13-May-20
Price @ Call: 1341.54
Target: 1640
BUY
We have factored in effect of Covid-19 pandemic and industry slow down in the sales figures. Hence, we expect the company to show a revenue growth of 4% in FY20 with similar PAT margins as reported in FY19. However, we expect the growth in FY21 to reduce down to 1.5% and resume its growth trajectory in FY22. We have forecasted a revenue growth of 3.52% CAGR over FY 19-22E and derived with revenue of Rs. 4950.7 Cr for FY22E. We expect the FY22E EPS to be Rs. 36.44 and the PAT margin to be ~20%. We have assigned a P/E multiple of 45x and arrive at a Target Price of Rs. 1,640 which is an upside of ~22% from current price of Rs. 1,339. We initiate coverage on Colgate Palmolive (India) Ltd with a BUY rating over an investment horizon of 20-24 months.
Prabhudas Lilladher
31-Jan-20
Price @ Call: 1395.75
Target: 1270
REDUCE
We believe slowdown in category growth, poor visibility on market share gains and lack of visible success in non-oral care segments will remain a drag. We estimate 6% volume growth and 9.4% PAT CAGR over FY20-22. We value the stock at 35xFY22 EPS and arrive at a target price of Rs 1270 (earlier 1257 at 35xSept21 EPS). We recommend switch from Colgate to HUVR. Retain Reduce.
COLPAL Share Price Target - Broker Reports - 2019
Motilal Oswal
26-Nov-19
Price @ Call: 1511.95
Target: 1815
BUY
We remain bullish on CLGT from the medium-term perspective, given its reasonable valuations (39.7x FY21E EPS – a huge discount to MNC peer multiples of 50x-56x), likely escalation in earnings momentum and sharp potential improvement in the already impressive RoCE. Targeting 45x Sep’21E, we maintain our target price of INR1,815 with a Buy rating.
Geojit Financial Services
4-Nov-19
Price @ Call: 1534.25
Target: 1632
HOLD
We estimate PAT to grow at 15.4% FY19-21E CAGR and EBITDA margin to improve to ~29.0% by FY21E. We believe that even though the long-term outlook is positive for the company, the management’s focus on regaining market share along with heavy competition and difficult macro environment will put pressure on the margins in the near future. We reiterate our HOLD rating with a target price of Rs 1,632 based on 43x FY21E EPS.
Prabhudas Lilladher
24-Oct-19
Price @ Call: 1559.94
Target: 1267
REDUCE
We believe slowdown in category growth, poor visibility on market share gains and low growth in premium segment are near term headwinds. We estimate 5.7% volume growth and 11% PAT CAGR over FY19-22. We value the stock at 35xSept21 EPS and arrive at a target price of Rs 1267 (earlier 1240 at 36xJune21 EPS). We believe valuation gap between CLGT and HUL has narrowed from 28% to <13% whereas HUL offers much better growth visibility and strong product profile. We recommend switch from Colgate to HUVR. Retain Reduce.
Prabhudas Lilladher
3-Sep-19
Price @ Call: 1274.35
Target: 1159
REDUCE
Although Colgate is indicating intent to grow personal care business (5% of sales), its focus on niche premium segments (hand and body wash and now Palmolive Facial bars) remains a hurdle. We believe CLGT will continue to trade at a discount to peers due to single category dependence and sustained loss of share in key category. We value the stock at 35xJune21 EPS (36x earlier) and cut target price to Rs1160 (Rs1208 earlier). Downgrade to Reduce.
Motilal Oswal
19-Jul-19
Price @ Call: 1206.1
Target: 1400
BUY
Valuation and view: We lower our growth assumption for FY20 post results, leading to changes to our model. Consequently, there is a minor cut in our FY20/21 EPS estimate. Although CLGT expects a demand recovery in the coming quarters, near-term volume growth is likely to be in mid-single-digits, despite stability attained in market share in the previous quarter. Management’s decision to place primacy on volume-led sales growth will likely restrict near-term margin expansion, in our view. However, a few factors are in CLGT’s favor from the medium-term perspective – (a) the toothpaste market share hemorrhage appears to have abated after three years, (b) there is evident traction driven by herbal and other launches and (c) valuations are relatively less expensive at ~35x FY21E EPS, ~7% discount to our ex-cigarette and alcohol consumer peer valuations. With return ratios superior to peers (barring HUL) and likely to improve further due to better utilization of expanded capacity, such a discount is unwarranted when execution starts improving. Valuing the company at 40x FY21 EPS, we derive a target price of INR1,400. Maintain Buy.
Dolat Capital
19-Jul-19
Price @ Call: 1206.1
Target: 1329
ACCUMULATE
We believe that its volume growth should recover further on a favorable base. Also, as the distribution reach of Swarna Vedshakti continues to rise, the company’s market share in the natural category is likely to increase further. The deceleration in Patanjali sales should also help Colgate to regain some lost market share. We maintain our FY20E and FY21E EPS at Rs30.7 and Rs 33.2, respectively, as our hypothesis of improvement in volume growth seems to be true. We value the stock at 40x FY21 EPS to arrive at a TP of Rs 1,329. Maintain Accumulate.
ICICIdirect.com
19-Jul-19
Price @ Call: 1206.1
Target: 1250
HOLD
CPIL has one of the widest distribution networks in India, spanning across ~6 million outlets across the country. Increasing its distribution network would help enhance its volume growth. To increase its presence in rural areas, CPIL has undertaken initiatives like Project Jagruti and Disha for the same. Though the company has been able to stabilise its market share from Q2FY19, we believe there is limited upside (~37x P/E at FY21 EPS) for a single product category company, which is already penetrated by about 88%. We believe unless CPIL takes price hikes, it would be difficult for the company to maintain its margins as its volume growth has been subpar. We reiterate our HOLD rating on CPIL with a revised target price of Rs 1250/share.
Nirmal Bang
19-Jul-19
Price @ Call: 1206.1
Target: 1320
ACCUMULATE
We expect margins to come under pressure going forward, as the company pursues its intent to drive topline growth and gain market share which would require higher investments in A&P spends and increased discounting considering the competitive intensity is fairly high and category growth remains low. We believe that the company may be able to gradually gain market share but margins will suffer because of elevated advertising and promotional spending. Hence, we expect margin expansion to remain modest because of these concerns. We have retained our Accumulate rating on CLGT, with a target price (TP) of Rs1,320 (unchanged) based on a P/E multiple of 38x, implying an upside of 10% from the current market price or CMP.
ICICIdirect.com
29-May-19
Price @ Call: 1180
Target: 1250
HOLD
CPIL has one of the widest distribution networks in India, which spans across ~6 million outlets across the country. Going forward, the increasing distribution network would help enhance the volume growth of the company. For increasing its presence in rural areas, CPIL has undertaken initiatives like Project Jagruti and Disha for the same. Though the company has been able to stabilise its decline in market share from Q2FY19, we believe there is limited upside (~37x P/E at FY21 EPS) for a single product category company, which is already penetrated by about 88%. We reiterate our HOLD rating on CPIL with a revised target price of Rs 1250/share.
Nirmal Bang
28-May-19
Price @ Call: 1180
Target: 1320
ACCUMULATE
We expect CLGT to continue its trajectory of single-digit revenue growth over the medium term. In our opinion, the possibility of margin expansion is limited because of higher competitive intensity, slow pace of premiumisation and moderate category growth. Therefore, we have retained our Accumulate rating on CLGT (after a slight revision to our estimates) with a revised target price of Rs1,320 (from Rs1,370 earlier) based on a P/E multiple of 38x, implying an upside of 12% from the CMP.
Prabhudas Lilladher
28-May-19
Price @ Call: 1180
Target: 1220
HOLD
CLGT mgt does not seem confident to achieve double digit topline growth and is looking at recalibrating advertising spends and mediums to sustain margins. We believe slowdown in category, low growth in premium segment, cannibalization by Swarna Vedshakti and renewed aggression by Patanjali will prevent significant increase in growth rates. We estimate 6% volume growth and 13.4% PAT CAGR over FY19-21. We value the stock at 36xFY21 EPS and assign a target price of Rs1230 (earlier 1258 at 36.5xFY21 EPS). Retain “Hold”.
ICICIdirect.com
28-Jan-19
Price @ Call: 1287.95
Target: 1350
HOLD
Motilal Oswal
25-Jan-19
Price @ Call: 1321.9
Target: 1540
BUY
COLPAL Share Price Target - Broker Reports - 2018
ICICIdirect.com
31-Oct-18
Price @ Call: 1112.23
Target: 1200
HOLD
HDFC Securities
30-Oct-18
Price @ Call: 1103
Target: 1163
NEUTRAL
Edelweiss
30-Oct-18
Price @ Call: 1103
Target: 1206
HOLD
Motilal Oswal
30-Oct-18
Price @ Call: 1103
Target: 1340
BUY
Prabhudas Lilladher
29-Oct-18
Price @ Call: 1105.85
Target: 1157
HOLD
ICICIdirect.com
27-Jul-18
Price @ Call: 1090.97
Target: 1150
HOLD
HDFC Securities
27-Jul-18
Price @ Call: 1090.97
Target: 1185
NEUTRAL
Motilal Oswal
27-Jul-18
Price @ Call: 1083.9
Target: 1360
BUY
KRChoksey
26-Jul-18
Price @ Call: 1124.7
Target: 1321
BUY
Dolat Capital
26-Jul-18
Price @ Call: 1124.7
Target: 1200
ACCUMULATE
Edelweiss
26-Jul-18
Price @ Call: 1124.7
Target: 1206
HOLD
Indiabulls Ventures
27-Jun-18
Price @ Call: 1187.22
Target: 1360
BUY
Kotak Securities
28-Jun-18
Price @ Call: 1178.5
Target: 1300
ADD
Motilal Oswal
21-May-18
Price @ Call: 1215.06
Target: 1420
BUY
Prabhudas Lilladher
21-May-18
Price @ Call: 1215.06
Target: 1075
REDUCE
Edelweiss
2-Apr-18
Price @ Call: 1056.75
Target: 1200
HOLD
HDFC Securities
12-Mar-18
Price @ Call: 1035.19
Target: 1204
BUY
Reliance Securities
8-Mar-18
Price @ Call: 1044
Target: 1323
BUY
Motilal Oswal
5-Feb-18
Price @ Call: 1115.31
Target: 1365
BUY
Edelweiss
6-Feb-18
Price @ Call: 1120.95
Target: 1200
HOLD
Prabhudas Lilladher
5-Feb-18
Price @ Call: 1115.31
Target: 1040
REDUCE
Reliance Securities
9-Jan-18
Price @ Call: 1117.15
Target: 1235
BUY
COLPAL Share Price Target - Broker Reports - 2017
Motilal Oswal
7-Dec-17
Price @ Call: 1039.5
Target: 1355
BUY
JM Financial
23-Oct-17
Price @ Call: 1040
Target: 1170
HOLD
ICICIdirect.com
23-Oct-17
Price @ Call: 1040
Target: 1115
HOLD
KRChoksey
23-Oct-17
Price @ Call: 1040
Target: 1145
ACCUMULATE
Motilal Oswal
17-Oct-17
Price @ Call: 1057
Target: 1325
BUY
Motilal Oswal
3-Aug-17
Price @ Call: 1083
Target: 1285
BUY
JM Financial
3-Aug-17
Price @ Call: 1083
Target: 1135
HOLD
KRChoksey
3-Aug-17
Price @ Call: 1080
Target: 1145
ACCUMULATE
ICICIdirect.com
6-Jul-17
Price @ Call: 1114
Target: 1150
HOLD
IIFL
13-Jun-17
Price @ Call: 1081
Target: 1320
BUY
Motilal Oswal
15-May-17
Price @ Call: 994
Target: 1180
BUY
KRChoksey
15-May-17
Price @ Call: 994
Target: 1059
ACCUMULATE
Motilal Oswal
17-Mar-17
Price @ Call: 989
Target: 1170
BUY
COLPAL Share Price Target - Broker Reports - 2016
Edelweiss
24-May-16
Price @ Call: 834
Target: 917
HOLD
Motilal Oswal
25-May-16
Price @ Call: 835
Target: 942
BUY
Religare
25-May-16
Price @ Call: 832
Target: 800
SELL
Reliance Securities
1-Nov-16
Price @ Call: 971
Target: 1105
BUY
ICICIdirect.com
1-Nov-16
Price @ Call: 971
Target: 1042
HOLD
Religare
1-Nov-16
Price @ Call: 958.6
Target: 920
SELL
Motilal Oswal
13-Oct-16
Price @ Call: 930.4
Target: 1090
BUY
Edelweiss
8-Aug-16
Price @ Call: 1015
Target: 1084
HOLD
Religare
9-Aug-16
Price @ Call: 974.4
Target: 920
SELL
Motilal Oswal
4-Jul-16
Price @ Call: 925
Target: 1090
BUY
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
- keyboard_arrow_down
COLPAL Peer Stocks - Share Price Targets
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.